股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股价交易异常波动的情况介绍 广州达安基因股份有限公司（以下简称"公司"、"本公司"或"达安基因"） 股票（证券简称：达安基因，证券代码：002030）交易价格连续 2 个交易日（2026 年 1 月 26 日、2026 年 1 月 27 日）收盘价格涨幅累计偏离 22.05%。根据《深圳 证券交易所交易规则》的有关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票异常波动情况，公司对有关事项进行了核查，并询问了公司控 股股东广州广永科技发展有限公司及间接控股股东广州金融控股集团有限公司， 有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期有媒体报道了可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、公司近期经营情况正常，内外部经营环境未发生重大变化。 证券代码：002030 证券简称：达安基因 公告编号：2026-002 广州达安基因股份有限公司 三、关于不存在应披露而未披露信息的说明 本公司董事会确认，本公 ...

（文章来源：证券时报网） 数据宝统计，截至09:57，达安基因成交额15.12亿元，创2022年5月25日以来新高。最新股价上涨 7.99%，换手率14.16%。上一交易日该股全天成交额为3.56亿元。 据天眼查APP显示，广州达安基因股份有限公司成立于1988年08月16日，注册资本140344.6032万人民 币。（数据宝） ...

Market Overview - On January 26, A-shares experienced a mixed adjustment, with the Shanghai Composite Index slightly down by 0.09%, while the Shenzhen Component Index and ChiNext Index fell by 0.85% and 0.91%, respectively. The STAR 50 Index dropped by 1.35%, and only the CSI 300 Index saw a minor increase of 0.1% [1] - The total trading volume in the two markets reached 3.25 trillion yuan, an increase of approximately 163 billion yuan compared to the previous day, with 1,538 stocks rising and 3,547 stocks falling. The net outflow of main funds was 121.6 billion yuan [1] Sector Performance - Precious metals, particularly silver, led the market with an increase of 10.89%, with 8 stocks hitting the daily limit [1] - Aerospace and military electronics sectors, including space station and phased array antenna concepts, saw significant declines [1] Company Highlights - Silver-related companies gained attention due to the recovery of precious metal concepts and the overall activity in the non-ferrous metal sector. Silver's dual industrial and financial attributes align with current market trends, attracting speculative and quantitative funds despite its lower revenue contribution [2] - Zijin Mining's significant investment plan to acquire an African gold mine for 28 billion yuan is a key driver of its popularity, reflecting a forward-looking strategy in resource allocation amid global industrial upgrades [2] - Tongling Nonferrous Metals benefits from tightening supply and demand in the global copper market, with increasing demand from the new energy and high-end manufacturing sectors driving copper prices up. The company has achieved technological breakthroughs in high-end products and is expected to enhance its resource self-sufficiency through its Ecuador Mirador copper mine project [2] - Hunan Silver, a leading player in the domestic silver processing sector, has performed well amid the overall strength of the non-ferrous metal sector, supported by institutional investment and multiple concept attributes [2] Emerging Trends - Zhejiang Wenhu Internet's business layout aligns with market trends, launching the "Pai Zhi" programmatic advertising tool in the AI marketing field and experiencing rapid growth in its digital human business in collaboration with ByteDance [3] - Wangsu Technology benefits from the explosive demand for AI computing power and the rising popularity of the cloud computing sector, with its strategic transition to edge computing nodes receiving unexpected orders [3] - Da'an Gene's focus on the "Nipah virus" testing theme resonates with market trends, leveraging its position as a leader in the molecular diagnostic reagent industry [3] - Leo Group is in a critical business transformation phase, focusing on AI applications and digital marketing, which has attracted market attention [3] Popular Stocks - The top ten popular stocks in A-shares include Silver Nonferrous Metals, Zijin Mining, Tongling Nonferrous Metals, Hunan Silver, Zhejiang Wenhu Internet, Wangsu Technology, Da'an Gene, Leo Group, Aerospace Electronics, and BlueFocus [3]

Group 1 - The recent outbreak of Nipah virus in West Bengal, India, has led to 5 confirmed cases, with one patient in critical condition, prompting enhanced preventive measures in neighboring countries like Thailand and Nepal [1] - Nearly 100 individuals have been placed under home quarantine, and infected patients are receiving treatment in hospitals in Kolkata and surrounding areas [1] - The Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and potentially fatal encephalitis, and there is currently no approved vaccine or specific treatment available [1][4] Group 2 - The stock prices of vaccine and in vitro diagnostic (IVD) sectors surged following the news, with companies like Hualan Biological (301207) and Jindike experiencing significant gains, reaching their daily limit [1][2] - The vaccine index rose by 6.60%, with notable increases in stock prices for companies such as Hualan Vaccine (20.00%), Jindike (19.98%), and Zhifei Biological (14.87%) [2] - The market response indicates a heightened interest in companies involved in vaccine development and diagnostic testing related to the Nipah virus [1][8] Group 3 - Nipah virus is classified as a high-pathogenicity pathogen with a mortality rate ranging from 40% to 75%, and it has been recognized as a significant public health threat for over 25 years [3][5] - The virus's natural reservoir is fruit bats, which can transmit the virus through contaminated food or environments, and outbreaks have primarily occurred in South and Southeast Asia [3][5] - Current detection methods include antibody and nucleic acid testing, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus detection [6][7] Group 4 - Companies are actively developing testing solutions, with Zhijiang Biological's Nipah virus PCR test kit achieving high sensitivity and rapid results, and Daan Gene's kit also showing promising detection capabilities [7] - Research into vaccines for Nipah virus is ongoing, with some candidates entering clinical trials, and monoclonal antibodies showing potential in compassionate use [8] - The stock prices of companies involved in vaccine development, such as Watson Bio, Zhifei Bio, and Hualan Vaccine, have seen increases, reflecting investor optimism regarding potential solutions to the Nipah virus threat [8]

（记者 曾健辉） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，达安基因1月26日晚间发布公告称，近日，广州达安基因股份有限公司取得国家药品监督 管理局颁发的医疗器械注册证一个。产品名称为"基因测序仪"。 ...

证券代码：002030 证券简称：达安基因 公告编号：2026-001 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督管 理局颁发的医疗器械注册证一个，具体为： 医疗器械名称：基因测序仪，注册证编号：国械注准 20263220149。有效期 自批准之日起至 2031 年 1 月 22 日。适用范围：该产品采用可逆末端终止测序技 术，在临床上用于对来源于人体样本的脱氧核糖核酸（DNA）和核糖核酸（RNA） 进行测序，基因序列可用于辅助诊断疾病或疾病易感性。该仪器在临床上仅限于 与国家药品监督管理部门批准的体外诊断试剂以及软件配合使用，不用于人类全 基因组的测序或从头测序。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 2026 年 1 月 26 日 董 事 会 广州达安基因股份有限公司 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

截至1月26日收盘，猴痘概念上涨3.13%，位居概念板块涨幅第8，板块内，50股上涨，凯普生物、迈克 生物、之江生物等20%涨停，达安基因、科华生物等涨停，万孚生物、智飞生物、百普赛斯等涨幅居 前，分别上涨16.23%、14.87%、12.58%。跌幅居前的有谱尼测试、富祥药业、合富中国等，分别下跌 9.72%、5.51%、5.32%。 资金面上看，今日猴痘概念板块获主力资金净流入15.26亿元，其中，46股获主力资金净流入，6股主力 资金净流入超亿元，净流入资金居首的是智飞生物，今日主力资金净流入2.61亿元，净流入资金居前的 还有众生药业、君实生物、达安基因等，主力资金分别净流入2.23亿元、1.69亿元、1.65亿元。 今日涨跌幅居前的概念板块 | 688575 | 亚辉龙 | 1.73 | 2.31 | 1476.63 | 7.35 | | --- | --- | --- | --- | --- | --- | | 300439 | 美康生 | 5.17 | 7.59 | 1457.59 | 6.07 | | | 物 | | | | | | 300482 | 万孚生 | 16.23 | 15.99 | ...

截至1月26日收盘，禽流感概念上涨6.89%，位居概念板块涨幅第1，板块内，25股上涨，之江生物、华 兰疫苗等20%涨停，达安基因涨停，永顺生物、东方生物、莱茵生物等涨幅居前，分别上涨27.18%、 12.36%、9.05%。 今日涨跌幅居前的概念板块 （文章来源：证券时报网） 禽流感概念资金流入榜 物 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 禽流感 | 6.89 | 军工信息化 | -4.70 | | 金属铅 | 6.22 | 太赫兹 | -4.42 | | 金属锌 | 5.85 | 同花顺新质50 | -4.24 | | 黄金概念 | 5.02 | 军民融合 | -3.87 | | 动物疫苗 | 4.89 | 卫星导航 | -3.84 | | 芬太尼 | 4.18 | 商业航天 | -3.56 | | 金属铜 | 3.81 | 国产航母 | -3.52 | | 猴痘概念 | 3.13 | 减速器 | -3.51 | | 生物疫苗 | 2.98 | 大飞机 | -3.39 | | 金属钴 | 2.70 | 成飞概念 | -3 ...

Group 1 - The Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers, with nearly 100 individuals under home quarantine [1][2] - The virus has a high fatality rate of over 40%, with some reports indicating rates as high as 75%, and there is currently no effective vaccine or treatment available [2][3] - The outbreak has prompted heightened public health alerts globally, with neighboring countries like Thailand and Nepal increasing their screening and quarantine measures for travelers from India [3] Group 2 - The A-share market saw a surge in stocks related to influenza, virus testing, and vaccines, with several companies hitting their daily price limits [1][4] - Companies like Zhijiang Biology and Hualan Vaccine confirmed they have relevant products but currently lack orders from India, while others like Antu Biology and Shuoshi Biology are actively promoting their technical capabilities in response to the outbreak [4][5] - Some vaccine companies, such as Jindike, have stated they do not have any products related to the Nipah virus, indicating a divergence in market reactions among different sectors [5][6]